Staphylococcus Toxin-Mediated Motor Polyneuropathy

Abdullah M. Pervaiz, MD; Raheel Akhtar, MD; Melissa Mercado, MD

Background: Staphylococcus aureus infection is known to cause a variety of neurologic complications, most involving the CNS (1). Cases of S. aureus affecting the peripheral nervous system have been rarely reported in the literature. In this case report, we describe an instance of S. aureus toxin-mediated motor polyneuropathy presenting as flaccid quadriplegia.

Case Description: A 64-year-old female with mantle cell lymphoma on oral chemotherapy with ibrutinib presents with malaise and progressive ascending bilateral lower extremity weakness. Blood cultures resulted positive for methicillin-sensitive S. aureus, and she was initiated on antibiotics. Imaging studies and laboratory workup were negative for other causes of acute flaccid quadriplegia. Patient had complete resolution of her neurologic deficits with antibiotic therapy. It was determined that the likely diagnosis was Staphylococcus toxin-mediated motor polyneuropathy.

Conclusions: Staphylococcal-mediated motor polyneuropathy resulting in acute flaccid quadriplegia is a rare but treatable complication of bacteremia and should remain a diagnosis of exclusion.

Key Words: bacteremia; methicillin-sensitive Staphylococcus aureus; motor neuropathy; quadriplegia; septic shock; Staphylococcus aureus toxin

Staphylococcus aureus infection is known to cause a variety of neurologic complications, most involving the CNS (1). Cases of S. aureus affecting the peripheral nervous system...
extremities. Repeat blood cultures which were drawn 2 days after her presentation were negative which correlated with the timing of resolution of her paresis. In light of complete resolution of her motor deficits, nerve conduction studies were deferred, and it was determined that the likely diagnosis was Staphylococcus toxin-mediated motor polyneuropathy. The source of bacteremia was determined to be a central venous access device in her right chest which was placed 2 years prior to presentation when she was on IV chemotherapy with rituximab. Treatment with IV rituximab was discontinued after 4 months due to severe thrombocytopenia after which oral ibrutinib was initiated. Our patient’s central venous access device remained in place and was primarily used for blood draws. The port was removed prior to discharge and blood cultures remained negative. The patient subsequently followed up with her oncology office after 4 weeks from discharge and was noted to have resolution of laboratory derangements seen on initial presentation (Table 1) and continued to have 5/5 strength in her upper and lower extremities.

### DISCUSSION
The differential diagnoses list for diffuse weakness in the setting of bacteremia is broad and includes generalized malaise/fatigue, spinal epidural abscess, meningitis, ischemic or hemorrhagic stroke, myelitis, exacerbation of underlying benign polyneuropathies, postinfectious autoimmune demyelinating neuropathies, and medication/antibiotic-induced neuropathies. Generalized malaise does not typically present with a flaccid para- or quadriplegia, however, and one would expect deep tendon reflexes to be preserved. Spinal epidural abscesses may present with progressive ascending weakness and may cause a flaccid quadriplegia if present in the cervical spine; however, patients typically complain of neck or back pain, and lower extremities may actually be hyperreflexic with clonus or upgoing toes. Cerebral complications such as meningitis or stroke may also present with upper motor neuron findings, but level of consciousness is not usually preserved, as it was in our patient. Workup of any patient with bacteremia and any focal neurologic deficits including coma should always begin with a plain CT of the head to rule out subacute ischemic strokes or hemorrhages, although this will not rule out an acute infarct. Although infectious myelitis is more frequently virally mediated, some bacteria such as mycoplasma, Streptococcus pneumoniae, and Neisseria meningitidis have been described to cause direct spinal cord infection (2). Patients with profound diabetic or vitamin deficiency-associated polyneuropathies may experience exacerbation of their symptoms in the setting of any acute illness, but these tend to be mixed sensory-motor neuropathies and decreased sensation in a stocking/glove distribution is usually found on examination. Antibiotic-induced neuropathies, including from linezolid, have been previously described, but these tend to occur after prolonged administration of the medication rather than upon presentation to the emergency department (3). Our patient was not on antibiotic therapy prior to admission.

Although a rare cause for acute quadriplegia, tick-borne illnesses need to be considered in the Northeastern United States. Tick Paralysis is a neurotoxic poisoning which occurs after tick attachment and injection of potent salivary toxins. After approximately 4–7 days, symptoms begin with generalized weakness and malaise with ascending paralysis ensuing in a mean of 1.4 days (range, 1–10 d). Other symptoms include diplopia, dysphagia, dysarthria, ataxia, and it is frequently misdiagnosed as GBS (4, 5). Over 40 tick species have been implicated in causing paralysis in humans and animals. The most common species are Dermacentor andersoni in Western Canada and the Pacific Northwest, and Dermacentor variabilis in the Southeastern United States. After removal of the tick rapid neurologic recovery is typically noted with full recovery in approximately 1–2 days (4). Our patient lived

---

TABLE 1. Laboratory Studies

| Laboratory Studies                        | Results on Initial Presentation | Results on Follow-Up |
|------------------------------------------|---------------------------------|----------------------|
| Complete blood picture                   |                                 |                      |
| WBC, k/mm³                               | 3.7                             | 4.2                  |
| Hemoglobin, g/dL                         | 8.6                             | 11.4                 |
| Hematocrit, %                            | 25.7                            | 35.5                 |
| Platelet count, k/mm³                    | 61                              | 220                  |
| Mean corpuscular volume, femtoliters     | 74.3                            | 85.3                 |
| Mean corpuscular hemoglobin, pg          | 24.9                            | 27.4                 |
| Mean corpuscular hemoglobin concentration, g/dL | 33.5                          | 32.1                 |
| Neutrophil, %                            | 45                              | 49.2                 |
| Lymphocyte, %                            | 37                              | 27.7                 |
| Monocyte, %                              | 10                              | 10.3                 |
| Eosinophil, %                            | 1                               | 1                    |
| Basophil, %                              | 1                               | 0.4                  |
| Metamyelocyte, %                         | 2                               | 0                    |
| Band, %                                  | 1                               | 0                    |

**Comprehensive metabolic panel**

| Test                        | Initial Presentation | Follow-Up |
|-----------------------------|----------------------|-----------|
| Sodium, mmol/L              | 133                  | 140       |
| Potassium, mmol/L           | 3.7                  | 4.1       |
| Chloride, mmol/L            | 98                   | 103       |
| Bicarbonate level, mmol/L   | 15                   | 25        |
| Glucose level, mg/dL        | 197                  | 223       |
| Blood urea nitrogen, mg/dL  | 57                   | 26        |
| Creatinine, mg/dL           | 2.9                  | 1.0       |
| Alkaline phosphatase, U/L   | 114                  | 214       |
| Aspartate aminotransferase, U/L | 175                 | 25        |
| Alanine aminotransferase, U/L | 415                 | 27        |
| Total bilirubin, mg/dL      | 1.2                  | 0.4       |

Initial laboratory studies notable for a leukopenia, thrombocytopenia, and acute kidney injury with resolution of her acute derangements on 4-wk follow-up after discharge.
in the North East, but she had not spent significant time outdoors and denied any recent tick or mosquito bites. After a meticulous skin examination, she was not found to have any ticks attached to her body. West Nile virus has been associated with neurologic manifestations, typically limb paresis, and paralysis due to viral involvement of the lower motor neurons of the spinal cord (anterior horn cells). However, presentation is usually asymmetric and often results in monoplegia (6). Our patient had ascending bilateral motor polyneuropathy.

Patients with a history of cancer, such as in our case, are at risk for bacteremia in the setting of immunocompromise and are also at risk for chemotherapy-induced neuropathy (7). Chemotherapy-induced neuropathies typically exhibit sensory deficits along with motor impairment, and the classes associated with polyneuropathy include vinca alkaloids, platinum drugs, taxanes, procarbazine, alkylating agents, and antimetabolites (8). Our patient was on oral chemotherapy for mantle cell lymphoma and was being treated with ibrutinib, a Bruton's tyrosine kinase inhibitor. Common neurologic side effects of ibrutinib include spontaneous bleeding notably into the subdural space. However, sudden paralysis or significant sudden neurologic compromise is not seen with patients on ibrutinib. (9)

*S. aureus* bacteremia has been recognized to cause CNS complications such as meningitis, septic cerebral emboli, spinal epidural abscess, or intracerebral hemorrhage; however, it is not frequently associated with peripheral nervous system involvement (1). There are only six published cases describing patients experiencing motor polyneuropathy as a result of *S. aureus*. Caksen et al (10) reported a 13-year-old boy who experienced peripheral sensorimotor neuropathy as well as a 65-year-old woman who developed quadriaparesis from an acute motor axonal neuropathy. Karmakar et al (11) also described three other cases of staphylococcal bacteremia complicated with polyradiculoneuropathy. These cases, like ours, improved shortly after antibiotic therapy and likely represented a direct toxin-mediated attack on the peripheral nervous system. Cases of secondary autoimmune-mediated syndromes such as GBS have also been published, although symptoms did not subside until 1 month following the infection, consistent with its usual course (12).

The pathophysiology underlying these cases is not well understood; however, direct axonal damage and demyelination may be implicated. Studies conducted on mice and rabbits have shown staphylococcal α-toxins to cause severe damage to the myelin sheath and injury to nerve axons (13). Anti-staphylococcal beta-hemolysin antibodies have also been linked to neurologic complications in humans (14).

**CONCLUSIONS**

Staphylococcal-mediated motor polyneuropathy resulting in acute flaccid quadriplegia is a rare but treatable complication of bacteremia and should remain a diagnosis of exclusion.

**REFERENCES**

1. Pruitt AA: Neurologic complications of infective endocarditis. *Curr Treat Options Neurol* 2013; 15:465–476
2. Kastenbauer S, Winkler F, Fesl G, et al: Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. *Arch Neurol* 2001; 58:806–810
3. Rho JP, Sia IG, Crum BA, et al: Linezolid-associated peripheral neuropathy. *Mayo Clin Proc* 2004; 79:927–930
4. Diaz JH: A 60-year meta-analysis of tick paralysis in the United States: A predictable, preventable, and often misdiagnosed poisoning. *If Med Toxicol* 2010; 6:15–21
5. Crawford P, Mitchell D: Tick paralysis as a cause of autonomic dysfunction in a 57-year-old female. *South Med J* 2009, 102:190–192
6. Jeha LE, Sila CA, Lederman RJ, et al: West Nile virus infection: A new acute paralytic illness. *Neurology* 2003; 61:55–59
7. Sommer C, Geber C, Young P, et al: Polyneuropathies. *Dtsch Arztebl Int* 2018; 115:83–90
8. Brzeziński K: Chemotherapy-induced polyneuropathy. Part I. *Pathophysiology. Contemp Oncol (Pozn)* 2012; 16:72–78
9. de Weerd I, Koopmans SM, Kater AP, et al: Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach. *Haematologica* 2017; 102:1629–1639
10. Caksen H, Uner A, Arslan S, et al: Severe peripheral polyneuropathy in a child with infective endocarditis caused by *Staphylococcus aureus*. *Acta Neurol Belg* 2004; 104:114–116
11. Karmakar PS, Chatterjee S, Mitra R, et al: Staphylococcal septicemia associated with peripheral neuropathy in three different clinical settings. *J Assoc Physicians India* 2013; 61:206–209
12. Baravelli M, Rossi A, Picozzi A, et al: A case of Guillain-Barré syndrome following *Staphylococcus aureus* endocarditis. *Int J Cardiol* 2007; 114:E53–E55
13. Harshman S, Burt AM, Robinson JP, et al: Disruption of myelin sheaths in mouse brain in vitro and in vivo by staphylococcal alpha-toxin. *Toxicon* 1985; 23:801–806
14. Uyeda CT, Gerstl B, Smith JK, et al: Anti-staphylococcal beta-hemolysin antibodies in humans with neurological disease. *Proc Soc Exp Biol Med* 1966; 123:143–146